# JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer

> **NCT04951947** · PHASE2 · RECRUITING · sponsor: **Hunan Province Tumor Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Small-cell Lung Cancer

## Interventions

- **DRUG:** JS201 combine with Lenvatinib

## Key facts

- **NCT ID:** NCT04951947
- **Lead sponsor:** Hunan Province Tumor Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-01
- **Primary completion:** 2024-12-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04951947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04951947, "JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04951947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*